Z

Zynerba Pharmaceuticals Inc
F:6ZY

Watchlist Manager
Zynerba Pharmaceuticals Inc
F:6ZY
Watchlist
Price: 1.26 EUR 2.44% Market Closed
Market Cap: 67.6m EUR

Relative Value

There is not enough data to reliably calculate the relative value of 6ZY.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

6ZY Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

6ZY Competitors Multiples
Zynerba Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Zynerba Pharmaceuticals Inc
F:6ZY
68m EUR 0 -2.1 -1.3 -1.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
519.1B USD 5.6 20.7 16.9 21.9
CH
Roche Holding AG
SIX:ROG
274.5B CHF 4.4 29 12.4 14.4
CH
Novartis AG
SIX:NOVN
219.7B CHF 5 19.4 15.5 20
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP 0 0.3 0 0
US
Merck & Co Inc
NYSE:MRK
277.1B USD 4.3 14.6 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.2 15.9 11.1 12.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
146.2B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
Z
Zynerba Pharmaceuticals Inc
F:6ZY
Average P/E: 21.2
Negative Multiple: -2.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
29
29%
1
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
0.3
37%
0
US
Merck & Co Inc
NYSE:MRK
14.6
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Z
Zynerba Pharmaceuticals Inc
F:6ZY
Average EV/EBITDA: 45.6
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
16.9
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
0
10%
0
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Z
Zynerba Pharmaceuticals Inc
F:6ZY
Average EV/EBIT: 99.8
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
1.9
98%
0
US
Johnson & Johnson
NYSE:JNJ
21.9
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.4
6%
2.4
CH
Novartis AG
SIX:NOVN
20
12%
1.7
UK
AstraZeneca PLC
LSE:AZN
0
23%
0
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5